Kate Khair
Overview
Explore the profile of Kate Khair including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
68
Citations
315
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
McKeown W, Hermans C, Unzu C, Kay M, Peyvandi F, Smith P, et al.
Haemophilia
. 2025 Jan;
PMID: 39868975
Introduction: Gene editing therapies offer the possibility of substantial improvement in treatment and quality of life for people with haemophilia (PWH) in a landscape of dynamic therapeutic advancement. Developing a...
2.
Valentino L, Khair K
Haemophilia
. 2024 Dec;
31(1):5-6.
PMID: 39632567
The shared decision-making (SDM) tool developed by the World Federation of Hemophilia (WFH) provides a clear and concise overview of the process by which people with haemophilia (PwH) can collaborate...
3.
Khair K, Fletcher S, Jenner K, Holland M
Haemophilia
. 2024 Nov;
30(6):1373-1382.
PMID: 39545676
Introduction: Glanzmann thrombasthenia (GT) is a platelet function disorder. Symptoms include bruising and bleeding, which may be severe and life-threatening. The day-to-day experiences of those affected remain poorly documented. Aims:...
4.
Khair K, Fletcher S, Boyton M, Holland M
Res Pract Thromb Haemost
. 2024 Nov;
8(7):102586.
PMID: 39526289
Background: Glanzmann thrombasthenia (GT) is a rare platelet function disorder that results in severe bleeding. We assessed clinical symptoms and psychological parameters to identify the unmet needs associated with GT....
5.
Hermans C, Valentino L, Thornburg C, Unzu C, Kay M, Peyvandi F, et al.
Haemophilia
. 2024 Oct;
30(6):1272-1280.
PMID: 39437171
Introduction: Despite the progress in gene editing platforms like CRISPR/Cas9 with the potential to transform the standard of care for haemophilia, the language used to explain and discuss gene editing...
6.
McLaughlin P, Chowdary P, Khair K, Smith C, Stephensen D, Hurley M
Pilot Feasibility Stud
. 2024 Oct;
10(1):128.
PMID: 39380074
Background: Chronic pain is reported by between 30 and 71% of people with haemophilia (PWH). Exercise is shown to be effective for pain management in other arthritides, but it remains...
7.
Russell J, Barber V, Chan E, Khair K, Rendle G, Wray J
Child Care Health Dev
. 2024 Jun;
50(4):e13292.
PMID: 38927003
Background: Non-invasive ventilation (NIV) for sleep-disordered breathing (SDB) in children and young people (CYP) can result in multiple health outcomes; however, adherence to NIV can be challenging. Suboptimally treated SDB...
8.
Chowdary P, Ofori-Asenso R, Nissen F, Grazzi E, Aizenas M, Moreno K, et al.
TH Open
. 2024 Apr;
8(2):e181-e193.
PMID: 38628421
Limited data relating to treatment burden, quality of life, and mental health burden of hemophilia A (HA) are currently available. To provide a comprehensive overview of unmet needs in people...
9.
Ozelo M, Hermans C, Carcao M, Guillet B, Gu J, Guerra R, et al.
Ther Adv Hematol
. 2024 Feb;
15:20406207231218624.
PMID: 38371314
Background: Real-world data assessing treatment outcomes in patients with hemophilia A in routine clinical practice are limited. Objective: To evaluate the effectiveness and safety of octocog alfa in patients with...
10.
Fletcher S, Jenner K, Holland M, Khair K
Orphanet J Rare Dis
. 2024 Feb;
19(1):59.
PMID: 38341591
Background: Gene therapy has the potential to offer people with haemophilia (PwH) a life free from bleeding and the burden posed by current treatment regimens. To date, gene therapy has...